PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

NCT05573893 · clinicaltrials.gov ↗

RECRUITING

Status

800

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms
Breast Cancer
Neoplasm Metastasis

Sponsor

AstraZeneca

Collaborators

[object Object]